We are live on ! Find out more
CNTA

Centessa Pharmaceuticals
CNTA

Delisted

CNTA was delisted on the 23rd of June, 2026.

Back to rankings

161 hedge funds and large institutions have $5.9B invested in Centessa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more capital invested

Capital invested by funds: $3.6B → $5.9B (+$2.3B)

48% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 33

42% more funds holding in top 10

Funds holding in top 10: 12 → 17 (+5)

38% more call options, than puts

Call options by funds: $31.9M | Put options by funds: $23.2M

14% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 44

10% more funds holding

Funds holding: 146 → 161 (+15)

5.18% less ownership

Funds ownership: 106.95% → 101.77% (-5.2%)

Holders
161
Holders Change
+15
Holders Change %
+10.27%
% of All Funds
1.97%
Holding in Top 10
17
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+41.67%
% of All Funds
0.21%
New
49
Increased
50
Reduced
44
Closed
33
Calls
$31.9M
Puts
$23.2M
Net Calls
+$8.7M
Net Calls Change
+$4.77M

Top Buyers

Rank Fund Capital Flow
1
PCM
Pentwater Capital Management
Florida
+$209M
2
Capital World Investors
Capital World Investors
California
+$94M
3
PBA
Paradigm Biocapital Advisors
New York
+$91.4M
4
Morgan Stanley
Morgan Stanley
New York
+$80.8M
5
EC
EcoR1 Capital
California
+$73.8M

Top Sellers

Rank Fund Capital Flow
1
GA
General Atlantic
New York
-$122M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$98.2M
3
ACA
Avoro Capital Advisors
New York
-$79.9M
4
SL
Siren LLC
Connecticut
-$76.1M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$60.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
SPIA
151
Steward Partners Investment Advisory
New York
$3.22K – – –
NS
152
NBC Securities
Alabama
$2.38K – – –
TRCT
153
Tower Research Capital (TRC)
New York
$1.63K -$27.9K -1,090 -96%
AP
154
Aspect Partners
Virginia
$1.19K -$4.22K -165 -85%
SS
155
SBI Securities
Japan
$1.19K +$128 +5 +20%
National Bank of Canada
156
National Bank of Canada
Quebec, Canada
$993 – – –
SIC
157
SJS Investment Consulting
Ohio
$874 +$179 +7 +47%
FFA
158
Farther Finance Advisors
California
$797 -$10.3K -402 -95%
PA
159
Parallel Advisors
California
$596 +$384 +15 New
EWA
160
EverSource Wealth Advisors
Alabama
$477 +$128 +5 +71%
Zurich Cantonal Bank
161
Zurich Cantonal Bank
Switzerland
$40 +$26 +1 New
T. Rowe Price Associates
162
T. Rowe Price Associates
Maryland
– -$98.2M -3,927,343 Closed
SC
163
Stempoint Capital
New York
– -$28.9M -1,154,114 Closed
SI
164
Sofinnova Investments
California
– -$27.6M -1,104,274 Closed
CC
165
Commodore Capital
New York
– -$25M -1,000,000 Closed
AC
166
Armistice Capital
New York
– -$12.5M -500,000 Closed
Walleye Capital
167
Walleye Capital
New York
– -$11M -441,160 Closed
SVCM
168
Saturn V Capital Management
Texas
– -$7.07M -282,692 Closed
WCM Investment Management
169
WCM Investment Management
California
– -$6.36M -257,190 Closed
BOCH
170
Blue Owl Capital Holdings
New York
– -$3.49M -139,450 Closed
Tudor Investment Corp
171
Tudor Investment Corp
Connecticut
– -$3.05M -121,810 Closed
RPAM
172
Rhenman & Partners Asset Management
Sweden
– -$2.5M -100,000 Closed
Verition Fund Management
173
Verition Fund Management
Connecticut
– -$2.37M -94,912 Closed
DP
174
Diadema Partners
New Jersey
– -$2.25M -90,000 Closed
DZ Bank
175
DZ Bank
Germany
– -$2.04M -81,525 Closed
4 5 6
7
8

CNTA Hedge Fund Activity: Q1 2026 in Review

161 of the 8,158 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q1 2026, worth a combined $5.9B — up 64% from $3.6B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new CNTA positions and 33 closed out — a net gain of 16 holders — while 50 added to existing stakes and 44 trimmed.

The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $209M. The largest seller was General Atlantic, cutting an estimated $122M.

  • 161 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q1 2026, up from 146 in Q4 2025.
  • Funds reported $5.9B of Centessa Pharmaceuticals stock for Q1 2026, up 64% quarter-over-quarter.
  • 49 funds opened new Centessa Pharmaceuticals positions in Q1 2026 and 33 closed out, a net change of +16 holders.
  • The largest Centessa Pharmaceuticals buyer in Q1 2026 was Pentwater Capital Management, an estimated $209M added.
  • The largest Centessa Pharmaceuticals seller in Q1 2026 was General Atlantic, an estimated $122M sold.

Based on aggregated 13F filings for Q1 2026.